angiotensin ii type 1 receptor

Telmisartan (BIBR 277) is an Angiotensin 2 Receptor Blocker. The mechanism of action of telmisartan is as an Angiotensin 2 Receptor Antagonist.

TRV055 acetate is a ligand of angiotensin II type 1 receptor and stimulates cellular Gq-mediated signaling.

E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.

Azilsartan Medoxomil Potassium (TAK-491 Potassium) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Olmesartan Medoxomil (Benicar) is an angiotensin II type 1 receptor blocker that is used to manage hypertension.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Valsartan (CGP 48933) is a tetrazole derivative and angiotensin II type 1 receptor blocker that is used to treat hypertension.

CL-329167 (compound 12) is an orally active, competitive angiotensin II receptor antagonist (IC50=6 nM) suitable for hypertension research.

UR-7247 is a novel orally active angiotensin II subtype I (AT1) antagonist, demonstrating very long pharmacological effects. in vivo studies indicate no significant difference between 10 mg UR-7247 and 100 mg losartan four hours post-administration, while in vitro blockade with 100 mg losartan exceeds that observed with UR-7247, confirming UR-7247’s extended plasma half-life potentially due to high-affinity protein binding, highlighting its long-lasting, well-tolerated AT1 receptor antagonism in healthy subjects.

Azilsartan-D5 is the deuterium-labeled Azilsartan. Azilsartan (T1057) is a specific antagonist of the angiotensin II type 1 receptor.

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

AT1R antagonist 3 (Compound 1) is an antagonist of the angiotensin II type 1 receptor (AT1R) and an inhibitor of the L-type calcium channel CaV1.2 (IC50=0.57 μM). It exhibits vasodilatory effects in isolated rat aorta (10 μM, 88.7%) and shows antihypertensive activity in rat models.

1H-1-ethyl Candesartan Cilexetil is a process-related impurity in the bulk synthesis of candesartan cilexetil, which is a potent, long-acting and selective angiotensin II type 1 receptor (AT1) antagonist.

Angiotensin Fragment 1-7 is a type 1 angiotensin II receptor agonist. In the renin-angiotensin system, angiotensin I is cleaved by the angiotensin-converting enzyme to form angiotensin II, which has effects on fluid and electrolyte, as well as homeostasis

L 158809 is an antagonist of the angiotensin II type 1 receptor.

FK-739 is an angiotensin type 1 receptor antagonist. FK 739 inhibits the specific binding of [125I]-angiotensin II to rat aortic smooth muscle cell membrane (IC50 = 8.6 nM) without displacing the specific binding of [125I]-angiotensin II to bovine cerebel

ZD 7155 hydrochloride is a potent and selective competitive antagonist for the angiotensin II type 1 (AT1) receptor. It displaces [125I]-angiotensin II binding in guinea pig adrenal gland membranes with an IC50 value of 3.8 nM.

Angiotensin II is a hormone that plays an important role in regulating blood pressure. Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor. Losartan is a mammalian AT1 receptor antagonist with a Ki value of 5-20 nM. In humans, losartan effectively controls hypertension while protecting renal function. Nitric oxide (NO) causes vasodilation and also inhibits platelet and neutrophil aggregation in the endothelium. NO-losartan A possesses similar anti-hypertensive effects to losartan, with the addition of the vasodilating effects of NO release.

4-hydroxy Valsartan is a major metabolite of the angiotensin II type 1 (AT1) receptor antagonist valsartan . It reduces platelet aggregation induced by epinephrine and collagen but not ADP in human whole blood.

Alamandine can be formed from angiotensin A by action of ACE-2 or directly from angiotensin-(1-7) by decarboxylation of its aspartate residue. The angiotensin A analog produces effects resembling those of Ang II (1-7). However, it acts independently of the two known vasodilators receptors of the RAS (Mas and angiotensin II type 2). To produce its effects, alamandine binds to the Mas-related receptor, MrgD. A novel orally active formulation of alamandine produced a long-term antihypertensive effect in spontaneously hypertensive rats and cardioprotective effects. These novel findings will be helpful for developing a new understanding of the RAS, a key regulator of blood pressure and fluid balance. The heptapeptide could serve as a model peptide, e.g. in the development and evaluation of analytical methods.

TRV055 is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling. TRV055 can be used to develop the Gq-biased AT1R agonists.